CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- 4 Grant or award Director acquired 56,623 shares (grant or award)
- 4 Open-market buy 10% owner bought 750,000 shares at $2.75 ($2,062,500)
- 4/A Derivatives Options or other derivatives
- 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 29,843 shares (to pay taxes)
- 4 Grant or award Chief Executive Officer acquired 892,500 shares (grant or award)
- 4 Grant or award President and Head of R&D acquired 324,500 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 431,000 shares (grant or award)
- 4 Open-market buy 10% owner bought 1,333,333 shares at $2.25 ($2,999,999)
- 4 Grant or award Director acquired 49,220 shares (grant or award)
- 4 Grant or award Director acquired 49,220 shares (grant or award)
- 4 Grant or award Director acquired 49,220 shares (grant or award)
- 4 Grant or award Director acquired 49,220 shares (grant or award)
- 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 1,288 shares (to pay taxes)
- 4 Grant or award Chief Financial Officer acquired 590,413 shares (grant or award)
- 4 Grant or award President and Head of R&D acquired 863,617 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 1,184,688 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 100,000 shares at $1.63 ($163,000)
Page 2 of 6 · 120 filings